Volume Alert - GERN 3.17 Geron Corp $GERN Hit a high today of 3.18 Closing the day 10:29 at 3.17 +0.06 +1.93% With a day low of 3.05 and a total volume of 1,418,466.
GERN Recent Posts: http://investorshangout.com/Geron-Corporation-GERN-54220/
GERN Geron Corp Recent Headline News
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 10:23AM CST
Regulatory updates from Gilead (GILD) and Regeneron (REGN) and Geron's (GERN) deal with J&J were the highlights last week in the biotech sector.
GILD: 101.89 (-0.45), GERN: 3.28 (+0.17), CLDX: 20.82 (+2.09), CYTR: 2.59 (-0.04), AMGN: 164.59 (+1.95), ABBV: 65.59 (+0.09), REGN: 413.04 (-2.21)
Can the Rally in Geron (GERN) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 7:43AM CST
Can the Rally in Geron (GERN) Shares Continue?
GERN: 3.28 (+0.17)
Most active Nasdaq-traded stocks
AP - Tue Nov 18, 12:25PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
GILD: 101.89 (-0.45), FB: 73.62 (+0.29), GERN: 3.28 (+0.17), DNDN: 0.13 (-0.02), SNSS: 2.01 (-0.12), MSFT: 48.45 (+0.23), INTC: 35.47 (+1.12), GRPN: 7.57 (+0.31), AAPL: 116.45 (+1.78), CSCO: 26.73 (+0.14), RFMD: 14.20 (+0.31)
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 10.73 (+0.76), GERN: 3.28 (+0.17), TKMR: 16.04 (-0.08), GALE: 1.86 (+0.05), XOMA: 4.55 (+0.44), EXEL: 1.72 (+0.02)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 107.89 (-0.87), GILD: 101.89 (-0.45), GERN: 3.28 (+0.17), MRK: 59.25 (-0.39), AZN: 74.37 (-1.01), PFE: 30.39 (-0.05), INCY: 71.54 (+0.24), BMY: 58.57 (-0.24), CTIC: 2.18 (unch), NVS: 95.33 (-0.40)
Hot Stock: Geron, Shares Gain 8.7% (GERN)
Comtex SmarTrend(R) - Mon Nov 17, 12:00PM CST
Geron (NASDAQ:GERN) is one of today's best performing low-priced stocks, up 8.7% to $3.00 on 2.7x average daily volume. Geron has traded 8.7 million shares thus far today, vs. average volume of 3.2 million shares per day. The stock has outperformed the Dow (8.7% to the Dow's -0.1%) and outperformed the S&P 500 (8.7% to the S&P's -0.2%) during today's trading.
GERN: 3.28 (+0.17)
J&J deal stokes Geron
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:42AM CST
GERN: 3.28 (+0.17)
Geron (GERN) Stock Surges Following Johnson & Johnson Licensing Deal
at The Street - Mon Nov 17, 9:40AM CST
Shares of Geron (GERN) soared in morning trading Monday after the company announced late last week it had licensed its blood disorder drug imetelstat to Johnson & Johnson JNJ.
GERN: 3.28 (+0.17)
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:25AM CST
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 301.78 (-1.83), GERN: 3.28 (+0.17), ILMN: 187.29 (-2.74), AFFX: 9.08 (+0.27)
Nasdaq stocks posting largest volume increases
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
NVEE: 11.78 (+0.08), GERN: 3.28 (+0.17), RDI: 11.86 (+0.23), RDIB: 11.84 (-0.16)
Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:00PM CST
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 301.78 (-1.83), JNJ: 107.89 (-0.87), GERN: 3.28 (+0.17), AFFX: 9.08 (+0.27)
Geron Set to Possibly Pullback After Yesterday's Rally of 19.48%
Comtex SmarTrend(R) - Fri Nov 14, 4:49PM CST
Geron (NASDAQ:GERN) traded in a range yesterday that spanned from a low of $2.72 to a high of $3.33. Yesterday, the shares gained 19.5%, which took the trading range above the 3-day high of $2.44 on volume of 31.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GERN: 3.28 (+0.17)
Halliburton and Geron are big market movers
AP - Fri Nov 14, 3:29PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
SINA: 37.77 (+0.49), AMZN: 330.82 (+4.28), JNJ: 107.89 (-0.87), HTZ: 22.71 (+0.53), GERN: 3.28 (+0.17), HAL: 49.08 (+0.65), JWN: 75.09 (+1.28), NOK: 7.78 (+0.04), BHI: 64.14 (+0.63)
Geron to Present at the Stifel Healthcare Conference
Thomson Reuters ONE - Fri Nov 14, 3:15PM CST
MENLO PARK, Calif., November 14, 2014 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the Stifel 2014 Healthcare Conference in New York. The presentation is scheduled to occur on Wednesday, November 19th at 1:50 p.m. Eastern Time.
GERN: 3.28 (+0.17)
Geron's Short Squeeze Is Here
Vahan Avetisyan - Seeking Alpha - Fri Nov 14, 2:40PM CST
Geron' s 2014 D eal to the Rescue Geron (NASDAQ: GERN ) surprised Thursday after-hours when it announced news that it entered into an exclusive worldwide license and collaboration agreement to develop its blood disorder drug imetelstat with...
JNJ: 107.89 (-0.87), GERN: 3.28 (+0.17)
Stock Market Today: Stocks Mixed as Retail Sales Climb, House OKs Keystone Pipeline
at The Street - Fri Nov 14, 2:36PM CST
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 37.77 (+0.49), JNJ: 107.89 (-0.87), HTZ: 22.71 (+0.53), VA: 33.75 (+0.54), GERN: 3.28 (+0.17), JWN: 75.09 (+1.28)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:46AM CST
ZIOP: 3.68 (+0.04), BSPM: 1.31 (+0.02), BDR: 2.02 (-0.10), ZAZA: 2.97 (-0.16), ACY: 8.65 (+0.15), NBS: 4.44 (+0.11), SYRX: 1.24 (-0.03), IAG: 2.26 (+0.05), THTI: 1.20 (-0.03), BITA: 87.40 (-0.73), VRTB: 4.78 (-0.22), OPTT: 1.03 (-0.04), INVT: 0.93 (+0.07), GERN: 3.28 (+0.17), VASC: 25.24 (+0.24), LOCM: 1.49 (+0.04), CTHR: 1.65 (+0.01), MOV: 25.67 (+0.41), IFON: 1.22 (-0.05), SVM: 1.55 (+0.03)
Traders Get Bullish on Shares of Geron, Shares Up 28.6% (GERN)
Comtex SmarTrend(R) - Fri Nov 14, 10:07AM CST
Geron (NASDAQ:GERN) is one of today's best performing low-priced stocks, up 28.6% to $2.97 on 5.5x average daily volume. Geron has traded 17.8 million shares thus far today, vs. average volume of 3.2 million shares per day. The stock has outperformed the Dow (28.6% to the Dow's -0.0%) and outperformed the S&P 500 (28.6% to the S&P's 0.1%) during today's trading.
GERN: 3.28 (+0.17)
GERN Recent Posts: http://investorshangout.com/Geron-Corporation-GERN-54220/
GERN Geron Corp Recent Headline News
Biotech Stock Roundup: Geron Soars on $935M J&J Deal, Gilead's Harvoni Approved in the EU - Analyst Blog
Arpita Dutt - Zacks Investment Research - Wed Nov 19, 10:23AM CST
Regulatory updates from Gilead (GILD) and Regeneron (REGN) and Geron's (GERN) deal with J&J were the highlights last week in the biotech sector.
GILD: 101.89 (-0.45), GERN: 3.28 (+0.17), CLDX: 20.82 (+2.09), CYTR: 2.59 (-0.04), AMGN: 164.59 (+1.95), ABBV: 65.59 (+0.09), REGN: 413.04 (-2.21)
Can the Rally in Geron (GERN) Shares Continue? - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Wed Nov 19, 7:43AM CST
Can the Rally in Geron (GERN) Shares Continue?
GERN: 3.28 (+0.17)
Most active Nasdaq-traded stocks
AP - Tue Nov 18, 12:25PM CST
NEW YORK (AP) — A look at Nasdaq 10 most-active stocks at 1 p.m.:
GILD: 101.89 (-0.45), FB: 73.62 (+0.29), GERN: 3.28 (+0.17), DNDN: 0.13 (-0.02), SNSS: 2.01 (-0.12), MSFT: 48.45 (+0.23), INTC: 35.47 (+1.12), GRPN: 7.57 (+0.31), AAPL: 116.45 (+1.78), CSCO: 26.73 (+0.14), RFMD: 14.20 (+0.31)
Today's Review on Biotech Equities - Exelixis, Geron, Tekmira Pharma, Galena Biopharma, and XOMA
PR Newswire - Tue Nov 18, 8:00AM CST
Investor-Edge has initiated coverage on the following equities: Exelixis Inc. (NASDAQ: EXEL), Geron Corporation (NASDAQ: GERN), Tekmira Pharmaceuticals Corporation (NASDAQ: TKMR), Galena Biopharma Inc. (NASDAQ: GALE), and XOMA Corporation (NASDAQ: XOMA). Free research on these five companies can be accessed at: http://investor-edge.com/register. The US markets on Monday, November 17, 2014, ended on a mixed note as the Dow Jones Industrial Average finished at 17,647.75, up 0.07% and the NASDAQ Composite closed at 4,671.00, down 0.37%. The S&P 500 finished the session 0.07% higher at 2,041.32. During the trading session, four out of ten sectors finished on a higher note. The S&P 500 Health Care Sector Index ended the day at 781.08, up 0.49%, with the index advancing 9.06% in the previous three months. Register for your complimentary reports on these five stocks at:
DRNA: 10.73 (+0.76), GERN: 3.28 (+0.17), TKMR: 16.04 (-0.08), GALE: 1.86 (+0.05), XOMA: 4.55 (+0.44), EXEL: 1.72 (+0.02)
Incyte Building Blockbuster Drug One Disease At A Time
at Investor's Business Daily - Mon Nov 17, 2:58PM CST
Sometimes, drug launches take a while to get off the ground. Incyte's only approved drug, Jakafi, has been on the market three years, but it's really only just getting started. Jakafi, sold in some markets as Jakavi, is approved for a rare...
JNJ: 107.89 (-0.87), GILD: 101.89 (-0.45), GERN: 3.28 (+0.17), MRK: 59.25 (-0.39), AZN: 74.37 (-1.01), PFE: 30.39 (-0.05), INCY: 71.54 (+0.24), BMY: 58.57 (-0.24), CTIC: 2.18 (unch), NVS: 95.33 (-0.40)
Hot Stock: Geron, Shares Gain 8.7% (GERN)
Comtex SmarTrend(R) - Mon Nov 17, 12:00PM CST
Geron (NASDAQ:GERN) is one of today's best performing low-priced stocks, up 8.7% to $3.00 on 2.7x average daily volume. Geron has traded 8.7 million shares thus far today, vs. average volume of 3.2 million shares per day. The stock has outperformed the Dow (8.7% to the Dow's -0.1%) and outperformed the S&P 500 (8.7% to the S&P's -0.2%) during today's trading.
GERN: 3.28 (+0.17)
J&J deal stokes Geron
Seeking Alpha - at Seeking Alpha - Mon Nov 17, 9:42AM CST
GERN: 3.28 (+0.17)
Geron (GERN) Stock Surges Following Johnson & Johnson Licensing Deal
at The Street - Mon Nov 17, 9:40AM CST
Shares of Geron (GERN) soared in morning trading Monday after the company announced late last week it had licensed its blood disorder drug imetelstat to Johnson & Johnson JNJ.
GERN: 3.28 (+0.17)
Strength Seen in Geron (GERN): Stock Surges 19.5% - Tale of the Tape
Zacks Equity Research - Zacks Investment Research - Mon Nov 17, 8:25AM CST
Geron (GERN) was a big mover last session, with shares surging over 19% on the day.
BIIB: 301.78 (-1.83), GERN: 3.28 (+0.17), ILMN: 187.29 (-2.74), AFFX: 9.08 (+0.27)
Nasdaq stocks posting largest volume increases
AP - Fri Nov 14, 5:03PM CST
NEW YORK (AP) — A look at the 10 biggest volume gainers on Nasdaq at the close of trading:
NVEE: 11.78 (+0.08), GERN: 3.28 (+0.17), RDI: 11.86 (+0.23), RDIB: 11.84 (-0.16)
Geron Collaborates with J&J for Imetelstat - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Fri Nov 14, 5:00PM CST
Geron Corporation (GERN), a clinical-stage biopharmaceutical company, announced that it has entered into an exclusive worldwide license and collaboration agreement with Janssen Biotech, Inc., a unit of Johnson & Johnson (JNJ).
BIIB: 301.78 (-1.83), JNJ: 107.89 (-0.87), GERN: 3.28 (+0.17), AFFX: 9.08 (+0.27)
Geron Set to Possibly Pullback After Yesterday's Rally of 19.48%
Comtex SmarTrend(R) - Fri Nov 14, 4:49PM CST
Geron (NASDAQ:GERN) traded in a range yesterday that spanned from a low of $2.72 to a high of $3.33. Yesterday, the shares gained 19.5%, which took the trading range above the 3-day high of $2.44 on volume of 31.4 million shares. Often times after large one-day gains, short term traders will seek to take profits and, as such, investors should be cautious.
GERN: 3.28 (+0.17)
Halliburton and Geron are big market movers
AP - Fri Nov 14, 3:29PM CST
NEW YORK (AP) — Stocks that moved substantially or traded heavily Friday on the New York Stock Exchange and the Nasdaq Stock Market:
SINA: 37.77 (+0.49), AMZN: 330.82 (+4.28), JNJ: 107.89 (-0.87), HTZ: 22.71 (+0.53), GERN: 3.28 (+0.17), HAL: 49.08 (+0.65), JWN: 75.09 (+1.28), NOK: 7.78 (+0.04), BHI: 64.14 (+0.63)
Geron to Present at the Stifel Healthcare Conference
Thomson Reuters ONE - Fri Nov 14, 3:15PM CST
MENLO PARK, Calif., November 14, 2014 - Geron Corporation (Nasdaq: GERN) today announced that John Scarlett, M.D., President and Chief Executive Officer, will present an overview of the company at the Stifel 2014 Healthcare Conference in New York. The presentation is scheduled to occur on Wednesday, November 19th at 1:50 p.m. Eastern Time.
GERN: 3.28 (+0.17)
Geron's Short Squeeze Is Here
Vahan Avetisyan - Seeking Alpha - Fri Nov 14, 2:40PM CST
Geron' s 2014 D eal to the Rescue Geron (NASDAQ: GERN ) surprised Thursday after-hours when it announced news that it entered into an exclusive worldwide license and collaboration agreement to develop its blood disorder drug imetelstat with...
JNJ: 107.89 (-0.87), GERN: 3.28 (+0.17)
Stock Market Today: Stocks Mixed as Retail Sales Climb, House OKs Keystone Pipeline
at The Street - Fri Nov 14, 2:36PM CST
U.S. stocks fluctuate on Friday, caught between better-than-expected retail sales and more worries of eurozone deflation.
SINA: 37.77 (+0.49), JNJ: 107.89 (-0.87), HTZ: 22.71 (+0.53), VA: 33.75 (+0.54), GERN: 3.28 (+0.17), JWN: 75.09 (+1.28)
Midday Gainers / Losers
Seeking Alpha - at Seeking Alpha - Fri Nov 14, 11:46AM CST
ZIOP: 3.68 (+0.04), BSPM: 1.31 (+0.02), BDR: 2.02 (-0.10), ZAZA: 2.97 (-0.16), ACY: 8.65 (+0.15), NBS: 4.44 (+0.11), SYRX: 1.24 (-0.03), IAG: 2.26 (+0.05), THTI: 1.20 (-0.03), BITA: 87.40 (-0.73), VRTB: 4.78 (-0.22), OPTT: 1.03 (-0.04), INVT: 0.93 (+0.07), GERN: 3.28 (+0.17), VASC: 25.24 (+0.24), LOCM: 1.49 (+0.04), CTHR: 1.65 (+0.01), MOV: 25.67 (+0.41), IFON: 1.22 (-0.05), SVM: 1.55 (+0.03)
Traders Get Bullish on Shares of Geron, Shares Up 28.6% (GERN)
Comtex SmarTrend(R) - Fri Nov 14, 10:07AM CST
Geron (NASDAQ:GERN) is one of today's best performing low-priced stocks, up 28.6% to $2.97 on 5.5x average daily volume. Geron has traded 17.8 million shares thus far today, vs. average volume of 3.2 million shares per day. The stock has outperformed the Dow (28.6% to the Dow's -0.0%) and outperformed the S&P 500 (28.6% to the S&P's 0.1%) during today's trading.
GERN: 3.28 (+0.17)
